Eisai Declines on Delay Preparing Cancer Drug Filing (Update2)

Eisai Co. drop the most in two years
in Tokio trading after the Nipponese drugmaker was forced to
delay seeking U.S. blessing for its first potentiality new medicine
since the Aciphex tummy ulceration treatment was released in 1999.

A 3rd form of patient surveys is required on Eisai's
experimental breast malignant neoplastic disease treatment before it can use to the
Food and Drug Administration, the Tokyo-based company said after
markets closed on Feb. 1. It had requested bypassing that step,
enabling a reappraisal as early as last quarter. Eisai now anticipates to
seek Food and Drug Administration blessing in the twelvemonth ending March 2010, it said.

The hold is frustrating Eisai President Haruo Naito's
attempts to develop replacements to Aciphex and Aricept, the
company's best-selling treatment for Alzheimer's disease. Aricept sales, which accounted for 40 percentage of grouping gross
last quarter, will slouch once the drug loses patent of invention protection
in the U.S. inch November 2010.

''The development hold is a disappointment,'' said
Hirohisa Shimura, an equities analyst at UBS Securities Japan
Ltd., inch a Feb. One report. ''Prospects for developing a new drug
candidate for Alzheimer's are also getting worse. Eisai may be
forced to concentrate on other stand-in compounds.''

Eisai, Japan's fourth-largest drugmaker, plunged as much as
260 yen, or 5.9 percent, to 4,130 hankering on the exchange, the
biggest diminution since Feb. 17, 2006. The shares drop 240 yen, or
5.5 percent, to 4,150 hankering at 1:15 p.m. local time.

Mizuho Securities Co. health-care analyst Hiroshi Tanaka
cut his evaluation on Eisai shares to ''reduce'' from ''hold,'' and
at least three brokerage firms lowered their terms mark for the
shares after the company's announcement.

Bristol-Myers

The Food and Drug Administration refused to hasten a reappraisal of Eisai's drug, known
as E7389 or eribulin mesylate, after the federal agency granted Bristol-
Myers Squibb Co. accelerated blessing for a similar treatment
last year, Eisai said.

New York-based Bristol-Myers won Food and Drug Administration blessing in October
for Ixempra, an injectable drug to handle the most advanced form
of breast malignant neoplastic disease and the first new type of chemotherapy for the
disease in 14 years.

The Food and Drug Administration granted Ixempra, also known as ixabepilone,
priority reappraisal last June, reducing the blessing procedure to six
months from at least 10, because of its possible to handle unmet
medical needs.

Women life in North United States have got the peak charge per unit of
breast cancer. About 180,000 new lawsuits were diagnosed in the U.S.
last year, and more than than 40,000 women died from the
disease, according to the American Cancer Society. Worldwide,
about 1.15 million new lawsuits of breast malignant neoplastic disease are diagnosed
annually, and 475,000 women die.

Eribulin mesylate incorporates a man-made word form of a substance
first scattered from a type of marine sponge in 1992, according
to Eisai. The Nipponese drugmaker is also investigating whether
its medical specialty can assist a broader scope of patients, including
those with prostate gland and lung cancer.

To reach the newsman on this story:
Kanoko Matsuyama in Tokio at at

Movie Review - Sicko

To begin with the end is probably the best way to approach the evaluation of any movie from filmmaker Michael Moore. That's because this propagandist is amazingly skilled at ending each of his films with something that no reasonable person could, or should, argue against. As you and the rest of the audience are drawn into spontaneous applause, as the credits roll, you forget the skillful nature he used to cherry pick facts which were convenient for his position and completely ignore any that suggest the bigger picture might just be, well, bigger.

It is indeed true, as the film suggests at the end, that it is sad, sickening and outrageous that rescue workers from 9/11 are able to get health care by going to Cuba but are apparently unable to get that care in the US. This stinks. It's bad. We should all hang our heads in collective shame about it.

As we back up, the premise of the film is clearly "Universal Health Care can do no wrong." To prove this, we first find a couple of Americans who were denied coverage for major trauma incidents: one who lost two fingers and had to pick which one he could afford to reattach and another who was denied coverage for an unconscious ambulance ride to the hospital because it wasn't pre-approved. Next, off to Canada we go where birds chirp merrily as every person is given the best medical care in the world, and with faster service than Moore receives at a fast food drive-through.

From Moore's account, the Canadian health care system is infallible and no one is ever left wanting.

Never mind the fact that I personally know more than one person who has had to leave Canada to get the surgery they need in America.

Also ignored is the fact that the medical devices we see used by the perfect health care systems of Canada, the UK, France and Cuba were mostly invented under the evil free-market system of the United States.

Shame on us for making life saving equipment. Will the evils of profit-minded researchers never end?

Yes, it's pretty hard to argue against the thought that all insurance programs are run by unholy hell spawn and Moore is very careful to spend most of his efforts bashing the system and not the individual caregivers. In fact, doctors are completely untouched in this film. Moore is after the insurance companies. After all, in the US we pay for our insurance and health care, but in these other countries it is "totally free."

I'll skip the Economics 101 lesson about what "free" means in this context.

No mention is made of prevention, diet or any "wellness" approaches to good health. Judging by Moore's own "healthy weight" it's pretty clear that he views health as something the doctor is supposed to care for only after you've fallen ill.

Another thought not covered by Sicko, but something Moore probably has no concern about anyway, is how Universal Health Care would be implemented in the US. In the 1950s, the AMA ran anti-socialized medicine campaigns and claimed it was the ultimate attack on freedom and a huge win for communism. But who would actually get the power with UHC? Universal Health Care is about guaranteed health care and is specifically not about freedom to affordable health care and choices for the type of care you receive. Would UHC simply make the American Medical Association into the total monopoly they wanted to become in 1847 when the AMA candidly told Congress that their intent was to drive away competition in the healing arts and raise the pay of the doctors who swore allegiance to the AMA?

Moore even compares UHC to the "utopia" of the US Post Office and the Public School System.

Wow, why didn't he include the DMV in that list to really give us confidence in the bureaucratic efficiency of this system?

There's no doubt that the richest and most powerful nation in the world should be able to provide care for the least rich and least powerful among us. This rational thought is the siren song that makes this film hard to argue with once you've been mesmerized by the finale. However, the aspects of Sicko which clearly make this a film and in no way a documentary is what is most damaging to the possibility of open dialog over such an issue.

The US sickness care system has problems. It has huge problems. Over 90 million suffer from chronic disease for which the "one drug for every symptom" approach of Western Medicine is a dismal failure. The World Health Organization has ranked the US 37th in overall wellness in the world and that's in spite of being the number one in per capita spending. If that kind of money can't provide care to all those who need it, there's a problem. However Moore would have you believe that the solution is a finger snap away and that the same application of a failed sickness-based paradigm will work just because it's "universal."